ACTRN12614000918628已完成未知
A multi-centre, double blind, randomised, placebo controlled trial to evaluate the effect of consuming Growing Up Milk ‘lite’ on body composition in children aged 12 – 23 months.
The University of Auckland, Faculty of Medical and Health Science0 个研究点目标入组 160 人开始时间: 2014年8月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 11 Months 至 12 Months（—）
- 性别
- All
入选标准
- •We will enrol children prior to the age of 12 months. They will remain in the study until they reach the age of 24 months.
- •Children will be eligible to enrol if they are healthy and aged less than 12 months
排除标准
- •Children will be ineligible to enrol if they:
- •Have a developmental disability (i.e. autism, intellectual disability)
- •Have a significant health impairment that is likely to influence their nutritional status (e.g. Cerebral Palsy or a chronic illness known to cause malabsorption)
- •Taking routine medication that is likely to interfere with iron absorption
- •Have iron deficiency anaemia (Hb<100g/L).
- •Have a medically diagnosed allergy to cow’s milk; or
- •Parents whose written or spoken English comprehension is likely to make participation difficult for them or result in incomplete data collection for the study.
研究者
相似试验
进行中（未招募）
1 期
A study to determine the optimal dose of Pollinex Quattro Grass 1.0 mL in the treatment of patients with allergic reactions due to grass pollen.Grass pollen-induced seasonal allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2017-000333-31-PLAllergy Therapeutics (UK) Ltd.440
进行中（未招募）
1 期
A study to determine the optimal dose of Pollinex Quattro Grass 1.0 mL in the treatment of patients with allergic reactions due to grass pollen.Grass pollen-induced seasonal allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2017-000333-31-ATAllergy Therapeutics (UK) Ltd.440
进行中（未招募）
1 期
A study to determine the optimal dose of Pollinex Quattro Grass 1.0 mL in the treatment of patients with allergic reactions due to grass pollen.Grass pollen-induced seasonal allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2017-000333-31-DEAllergy Therapeutics (UK) Ltd.440
进行中（未招募）
不适用
A study to learn more about the effects of a pain relief medicine called methoxyflurane (known as Penthrox(TM)) on pain caused by a minor injury. The effects will be compared to a dummy medicineAcute painMedDRA version: 14.0Level: LLTClassification code 10066714Term: Acute painSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2011-000338-12-GBMedical Developments International Limited300
已完成
2 期
A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren*s DiseaseNL-OMON47684niversity of Oxford, Research Services, Clinical Trials and Research Governance, Joint Research Office, Boundary Brook House35